Correction to: Structure-activity relationships and pharmacokinetic evaluation of L-cystine diamides as L-cystine crystallization inhibitors for cystinuria (Medicinal Chemistry Research, (2024), 33, 8, (1384-1407), 10.1007/s00044-024-03228-w)

Correction to: Medicinal Chemistry Research (2024) The original version of this article unfortunately contained errors in Table 1. (Table presented.) Effect of l-cystine diamides 3a–3j and 4a–4h on the aqueous solubility of l-cystine in comparison to l-CDME (1) and LH708 (2) Compound R Effect on L-cystine aqueous solubility Compound R Effect on L-cystine aqueous solubility EC₅₀ (nM)^a Ratio^b EC₅₀ (nM)^a Ratio^b (LH1726) 52.6 ± 0.8 0.81 (LH1734) 163.4 ± 10.8 0.26 (LH1729) 32.0 ± 2.5 1.34 (LH1735) 116.4 ± 6.1 0.37 (LH1730) 68.8 ± 4.1 0.62 (LH1737) 142.7 ± 9.8 0.30 (LH1731) 39.5 ± 1.3 1.08 (LH1738) 79.7 ± 7.7 0.54 (LH1732) 500.3 ± 26.5 0.09 (LH1736) 4150 ± 541 0.01 (LH1733) 108.0 ± 3.1 0.40 (LH1739) 114.3 ± 9.4 0.37 (LH1751) 51.2 ± 3.7 0.84 (LH1740) 163.3 ± 12.5 0.26 (LH1752) 36.5 ± 1.6 1.17 (LH1741) 160.2 ± 10.6 0.27 (LH1753) 25.1 ± 2.4 1.70 (L-CDME) 2621 ± 234 0.02 (LH1754) 120.2 ± 13.0 0.36 (LH708) 42.8 ± 0.7 1.00 ^aEC₅₀ refers to the inhibitor concentration required to achieve 50% of the maximal apparent aqueous solubility of l-cystine ^bRatio refers to the improvement in potency over LH708 The corrected Table 1 is presented here. The original article has been corrected.